Cognivue is a risk assessment test that objectively, quantitatively and reliably identifies changes in cognitive function that could be indicative of dementia or Alzheimer's disease.
Clinical cognitive testing solution
Cognivue objectively, quantitatively and reliably determines a patient’s level of risk for developing a cognitive impairment. Through early intervention, patient’s are able to preserve their cognitive health or establish a baseline cognitive risk score that can be monitored over time. It is the first computerized cognitive test cleared by the FDA for patients over the age of 55. It is based on years of research focusing on early detection of late-life cognitive decline (LLCD) and dementia. Here is how we are working with patients and health care providers to leverage its benefits.
For Primary Care Providers
No referrals are necessary. Cognivue is a rapid, office-based solution for routine cognitive function monitoring.
- 10 sub-tests in 10 minutes
- 4 key domains of the brain
- Test is reimbursable
For Patients and Family
Cognivue enables cognitive function testing, which allows for early identification and risk stratification. It can detect early signs cognitive decline for patients in all healthcare settings—working with their personal physician, who knows them best.
- Accessible testing across time and location
- Immediate results
- Single, quantitative cognitive function risk score
For Integrated Delivery Networks (IDNs) and Payors
By establishing an early baseline risk score, physicians are able to intervene and provide patient’s with an effective treatment plan. There are many effective treatment clinical outcomes, such as:
- Treating reversible dementia
- Managing co-morbidities
- Avoiding complications, polypharmacy, and procedures
For the Industry
Cognivue provides rapid, standardized CRO cognitive function testing of new molecules.
- CogniWheel™ global patient interface
- Cloud-based results, storage, and analytics
- Primary Care Physician (PCP) engagement in testing and monitoring of new treatments
Early and accurate diagnosis leads to better disease management, patient outcomes and improved quality of life. It also can lower state and patient costs through an orderly plan for care, rather than one filled with crisis, frequent hospital visits and unanticipated expenses. Alzheimer’s can be a cruel disease. While there is yet no cure, early diagnosis and disease management can help ease the burden on patients, their families and the state budget. We urge our lawmakers to support this reasonable budget allocation.Bruce L. Miller, professor of neurology at the University of California, San Francisco, and director of the UCSF dementia center.